Changes for page Neurodiagnoses

Last modified by manuelmenendez on 2025/03/03 22:46

From version 34.1
edited by manuelmenendez
on 2025/02/01 13:54
Change comment: There is no comment for this version
To version 24.1
edited by manuelmenendez
on 2025/01/29 18:46
Change comment: There is no comment for this version

Summary

Details

Page properties
Content
... ... @@ -15,19 +15,8 @@
15 15  (((
16 16  = What is this about and what can I find here? =
17 17  
18 -= **Overview** =
18 +== **Overview** ==
19 19  
20 -
21 -The classification and diagnosis of **central nervous system (CNS) diseases** have long been constrained by **traditional phenotype-based approaches**, which often fail to capture the **complex pathophysiological mechanisms, molecular biomarkers, and neuroanatomical changes** that drive disease progression. **Neurodegenerative and psychiatric disorders**, for example, exhibit significant **clinical overlap, co-pathology, and heterogeneity**, making current diagnostic models insufficient.
22 -
23 -This project proposes a **new diagnostic framework**—one that **shifts from symptom-based classifications** to an **etiology-driven, tridimensional system**. By integrating **genetics, proteomics, neuroimaging, computational modeling, and AI-powered annotations**, this approach aims to provide a **more precise, scalable, and biologically grounded method for diagnosing and managing CNS diseases**.
24 -
25 -The **AI-powered annotation system** plays a critical role by **structuring, interpreting, and tracking multi-modal data**, ensuring **real-time disease progression analysis, clinician decision support, and personalized treatment pathways**.
26 -
27 -=== **Project Aim** ===
28 -
29 -The project aims to develop a **tridimensional diagnostic framework** with an **AI-powered annotation system**, integrating **etiology, molecular biomarkers, and neuroanatomoclinical correlations** for **precise, standardized, and scalable CNS disease diagnostics**.
30 -
31 31  The //Tridimensional Diagnostic Framework// redefines CNS diseases can be classified and diagnosed by focusing on:
32 32  
33 33  * **Axis 1**: Etiology (genetic or other causes of diseases).
... ... @@ -34,6 +34,10 @@
34 34  * **Axis 2**: Molecular Markers (biomarkers).
35 35  * **Axis 3**: Neuroanatomoclinical correlations (linking clinical symptoms to structural changes in the nervous system).
36 36  
26 +
27 +[[For instance, neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]]
28 +
29 +
37 37  This methodology enables:
38 38  
39 39  * Greater precision in diagnosis.
... ... @@ -40,22 +40,10 @@
40 40  * Integration of incomplete datasets using AI-driven probabilistic modeling.
41 41  * Stratification of patients for personalized treatment.
42 42  
43 -== **The Role of AI-Powered Annotation** ==
44 -
45 -To enhance **standardization, interpretability, and clinical application**, the framework integrates **an AI-powered annotation system**, which:
46 -
47 -* **Assigns structured metadata tags** to diagnostic features.
48 -* **Provides real-time contextual explanations** for AI-based classifications.
49 -* **Tracks longitudinal disease progression** using timestamped AI annotations.
50 -* **Improves AI model transparency** through interpretability tools (e.g., SHAP analysis).
51 -* **Facilitates decision-making for clinicians** by linking annotations to standardized biomedical ontologies (SNOMED, HPO).
52 -
53 53  == **The case of neurodegenerative diseases** ==
54 54  
55 55  There have been described these 3 diagnostic axes:
56 56  
57 -[[Neurodegenerative diseases can be studied and classified in a tridimensional scheme with three axes: anatomic–clinical, molecular, and etiologic. CSF, cerebrospinal fluid; FDG, fluorodeoxyglucose; MRI, magnetic resonance imaging; PET, positron emission tomography.>>image:tridimensional.png||alt="tridimensional view of neurodegenerative diseases"]]
58 -
59 59  * (((
60 60  **Axis 1: Etiology**
61 61  
... ... @@ -85,6 +85,10 @@
85 85  * **Research**: By stratifying patients, reduces cohort heterogeneity in clinical trials.
86 86  * **Clinical Practice**: Provides dynamic diagnostic annotations with timestamps for longitudinal tracking.
87 87  
69 +== Who has access? ==
70 +
71 +We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
72 +
88 88  == How to Contribute ==
89 89  
90 90  * Access the `/docs` folder for guidelines.
... ... @@ -96,17 +96,9 @@
96 96  * Develop interpretable AI models for diagnosis and progression tracking.
97 97  * Integrate data from Human Phenotype Ontology (HPO), Gene Ontology (GO), and other biomedical resources.
98 98  * Foster collaboration among neuroscientists, AI researchers, and clinicians.
99 -
100 -== Who has access? ==
101 -
102 -We welcome contributions from the global community. Let’s build the future of neurological diagnostics together!
103 103  )))
104 104  
105 105  
106 -
107 -
108 -
109 -
110 110  (% class="col-xs-12 col-sm-4" %)
111 111  (((
112 112  {{box title="**Contents**"}}